The mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes. Celgene’s partners, and their investors, are concerned about the ramifications.

The $74bn mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes.

This week's round-up includes promotions at Astellas, new CSOs at MorphoSys and Tenaya, a new president and CMO at AZTherapies, new directors at BioScience Managers, plus board changes at Intec and Sigilon.

This week’s announcements include Valeant’s appointment of an executive vice president finance, Editas Medicine’s appointment of a chief scientific officer, Clintec’s appointment of AstraZeneca’s former global research director and various board appointments by Acadia, Scancell, PhaseRx and Gilead.